MLN8054

Modify Date: 2024-01-02 12:57:07

MLN8054 Structure
MLN8054 structure
Common Name MLN8054
CAS Number 869363-13-3 Molecular Weight 476.86
Density 1.2±0.1 g/cm3 Boiling Point 429.5±45.0 °C at 760 mmHg
Molecular Formula C25H15ClF2N4O2 Melting Point N/A
MSDS N/A Flash Point 213.5±28.7 °C

 Use of MLN8054


MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.

 Names

Name 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid
Synonym More Synonyms

 MLN8054 Biological Activity

Description MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
Related Catalog
Target

Aurora A:4 nM (IC50)

In Vitro MLN8054 is an ATP-competitive, reversible inhibitor of recombinant Aurora A kinase. MLN8054 is >40-fold more selective for Aurora A compared with the family member Aurora B. MLN8054 selectively inhibits Aurora A over Aurora B in cultured human tumor cells. MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines. MLN8054 effectively inhibits the growth of cells from diverse tissue origins with IC50 values ranging from 0.11 to 1.43 μM[1]. Treatment of human tumor cells grown in culture with MLN8054 shows a number of morphologic and biochemical changes associated with senescence[2].
In Vivo In the HCT-116 tumor-bearing mice, MLN8054 treatment inhibits tumor growth dose dependently. MLN8054 is generally well tolerated. MLN8054 also inhibits the growth of the PC-3 tumor xenograft in nude mice. MLN8054 Treatment Results in Inhibition of Aurora A, Accumulation of Mitotic Cells, and Apoptosis in vivo[1]. MLN8054 selectively inhibits Aurora A kinase activity when dosed at 30 mg/kg. At this dose in HCT116 tumor tissue, MLN8054 has been shown to inhibit Aurora A autophosphorylation, and induce an increase in the Aurora B substrate, pHisH3[2].
Cell Assay MLN8054 is added to human tumor cells in 2-fold serial dilutions to achieve final concentrations ranging from 10 to 0.04 mM. MLN8054 at each dilution is added in triplicate with each replicate on a separate plate. Cells treated with DMSO (n=6 wells per plate; 0.2% final concentration) served as the untreated control. The cells are treated with MLN8054 for 96 h at 37°C in a humidified cell culture chamber. Cell viability in each cell line is measured by using the Cell Proliferation ELISA, BrdU colorimetric kit[1].
Animal Admin Mice: Nude mice bearing HCT-116 tumors are treated orally once per day for 21 consecutive days with either vehicle control or MLN8054 at doses of 3, 10, or 30 mg/kg. Tumor volumes are measured by using a vernier caliper and calculated[1].
References

[1]. Manfredi MG, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11.

[2]. Huck JJ, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 2010 Mar;8(3):373-84.

 Chemical & Physical Properties

Density 1.2±0.1 g/cm3
Boiling Point 429.5±45.0 °C at 760 mmHg
Molecular Formula C25H15ClF2N4O2
Molecular Weight 476.86
Flash Point 213.5±28.7 °C
PSA 64.63000
LogP 2.02
Vapour Pressure 0.0±1.0 mmHg at 25°C
Index of Refraction 1.524
Storage condition -20°C

 Synonyms

Kinome_1204
S1100_Selleck
MLN 8054,MLN-8054
MLN 8054
Ethyl 8-methoxy-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxylate
1H-1-Benzazepine-4-carboxylic acid, 2,3,4,5-tetrahydro-8-methoxy-2-oxo-, ethyl ester
ZZL
MLN8054
Top Suppliers:I want be here




Get all suppliers and price by the below link:

MLN8054 suppliers


Price: $145/10mM*1mLinDMSO

Reference only. check more MLN8054 price